

## Prevention and intervention strategies for substance use disorder

Priya Sharma\*

\*Research Scholar, Shambhu Dayal (PG) College, [priya.sharma92@gmail.com](mailto:priya.sharma92@gmail.com)

### ABSTRACT

Substance use disorder (SUD) is still a major global health problem, for which traditional prevention and intervention are often hindered by access, stigmatization, and social structures. New opportunities like telehealth, peer support, and pharmacogenomics present themselves as possibilities for raising the outcomes of treatment and increasing accessibility. This review examines novel trends in the prevention and treatment of SUDs for the last decade, which include telehealth and virtual treatment, peer support and recovery coaching, and pharmacogenomics. Research from scholarly databases is reviewed to analyze the effectiveness of these strategies and the potential for increasing the availability of treatment services. Telehealth is useful in overcoming geographical and stigmatization barriers to care and in affording patients access to treatment. Several peer support interventions have been shown to have a beneficial influence on treatment participation as well as recovery. Pharmacogenomics has been advanced as a useful way to tailor pharmacological therapies to genetic differences, which may increase effectiveness and decrease relapse. Despite these gaps in knowledge territory showing such promising emerging trends to SUD treatment, challenges like stigma, access to resources, and funding gaps keep on existing. More investigation should be carried out in the future about such innovations and their impact and the policy agendas should aim at increasing the adoption of such methods into the conventional systems of treatment.

**Keywords:** *Substance use disorder, telehealth, peer support, pharmacogenomics, treatment innovation.*

### 1. INTRODUCTION

Substance Use Disorder (SUD) is a chronic, relapsing-remitting illness involving the compulsive use of psychoactive substances in a manner that produces harm to the individual and society. SUD is emerging as an important international public health issue that significantly affects morbidity and mortality and is associated with substantial costs. Substance dependence is defined as a maladaptive pattern of substance use that includes taking alcohol, illicit drugs prescription drugs, and medications, and the use persists even when there are negative consequences (Cooper, 2018). Substance use is said by the World Health Organization to be a risk factor for different diseases, both chronic, mental, and infectious. This disorder can occur in any person irrespective of age, gender, and income level, as such, it is a problem that affects everyone and should therefore be of concern to everyone.

#### Overview of Substance Use Disorder (SUD)

SUD is mostly diagnosed by the inability of an individual to moderate the use of substances in a manner that will not harm him/her. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), SUD is diagnosed when a person exhibits at least two of the following criteria over 12 months including at least three of the following within the past year of use substances in larger amounts or over a longer period than intended, being unable to stop or cut down use, spending significant time obtaining, using, or recovering from use, experiencing cravings, and continuing use despite knowledge of physical or psychological problems caused or exacerbated by substance use. SUD involves alcohol, nicotine, opioids, cocaine, methamphetamine, benzodiazepines, and painkiller among others (Memedovich, et al., 2018). The severity of the disorder can also be mild requiring a little treatment and the other extreme where the person is dependent on the substance and is completely functionally impaired. SUD has a profound physiological impact in that, the prolonged use of the substance normally leads to tolerance, withdrawal symptoms, and addiction. They happen in the brain's reward circuit that helps to lobby the substance use behavior and as a result, the addict is unable to quit substance use even when they realize the harm it causes them (Kamens et al., 2023). SUD is not just a decision that one makes but a disease that takes a lifelong treatment like any other disease type Diabetes or Hypertension for instance.

#### Global Impact of SUD

The situation with SUD is severe on the international level, and millions of people around the globe suffer from it. The Global Burden of Disease Survey 2019 showed that at least 271 million people or 5.5% of the global population aged between 15 and 64 had used illicit drugs in the last year. Alcohol use is one of the greatest preventable causes of death and disability worldwide, with around 3 million deaths every year linked to alcohol. Opioid use has also increased to alarming levels, especially in North America deaths caused by opioids have become epidemic (Bonk et al., 2020).

SUD is not only a personal, but also an economic tragedy The economic burden of SUD is overwhelming. NIDA, (2021) approximates that alcohol and drug abuse costs the United States alone more than \$ 740 billion every year, including costs of treating the effects of the substances, lost productivity, as well as costs of handling crimes committed under its influence. This is on top of the cost that substance abuse has in social terms, such as family breakups, increased crime rates, and

social disharmony. Moreover, SUD results in other coexisting diseases, and psychiatric disorders such as depression, anxiety, and psychosis (Memedovich et al., 2018). Perceived public beliefs about addiction entail social rejection and exclusion this makes people with addiction not seek treatment since they feel they will be rejected by society, making the problem worse and the access to the required healthcare services (Misra et al., 2021).

SUD also has severe impacts on public health systems because clients with the disorder often seek medical care, psychological treatment, and social services. Such demands exert pressure on the HC system, especially in Low- and Middle-Income (LAMI) countries that are grappling with a weak Healthcare (HC) system. Moreover, the Globalization of illicit drug business and substance trafficking has caused an addition to violence, criminal linkage, and human trafficking making the challenge of eradicating the vice even bigger globally.

### Purpose of Prevention and Intervention Strategies

Due to the disastrous consequences of SUD, there is a need to come up with and also enforce great measures for preventing and combating SUD. While prevention is an effort to minimize the conditions that facilitate substance use and abuse, intervention is an effort to help those already in the substance abuse vortices seek the right help at the right time. Both strategies are relevant for addressing the reduction of SUD effects on individuals and society.

Primary prevention aims at the Prohibition of initiation to substance use using methods like informational, community-based, and policy methods. Substance use risk factors include early use of the substance, peer pressure, family history of substance abuse, and environmental factors including accessibility of the substance (Grant et al., 2017). For instance, school-based prevention programs will reduce substance use among adolescents through positive health behavior and skills to counter pressure from peers (Hennessy & Tanner-Smith, 2015). Furthermore, anti-stigma public health interventions that target substance users and advocate for treatment-seeking behaviors are promising in getting people to seek help sooner (Miller & Rollnick, 2024).

Intervention strategies mainly aim at addressing SUD-suffering individuals. These are behavior therapies, medical management, and harm reduction interventions. Many have suggested that cognitive-behavioral therapies (CBT) are effective in promoting change in the patient's thought process and behaviors regarding substances (Carroll & Kiluk, 2017). Methadone or buprenorphine the medication-assisted treatment-agonist agents are used frequently for opioid use disorder and adjunct counseling is known to enhance the treatment outcomes (McElrath, 2018) as shown in Figure 1. There has also been an uptake of the harm reduction approach in the recent past, which gives a Vienna, no one is arguing that substance use is good, just that the consequences should not be catastrophic. These measures consist of needle distribution programs, licit injection facilities, and safe means of disposal of the substance (Fernandes et al., 2017).

These strategies' end-point is to decrease the rate of SUD, enhance the well-being of persons who have the disorder, and minimize the social price of substance use. Combining primary, secondary, and tertiary prevention means the client will get a holistic approach to SUD that will help him or her stay sober and healthy in the long run (Helle et al., 2022).



Figure 1: Substance Use Disorder

## 2. UNDERSTANDING SUBSTANCE USE DISORDER

### Definition and Criteria

SUD defines the condition where an individual persistently and compulsively uses psychoactive substances even where such use leads to harm. It is diagnosed depending on the DSM-5 criteria that include inability to control the use of the substance, cravings, and continuing to use the substance despite harm (Cooper, 2018). People with SUD may also

experience withdrawal, and build tolerance meaning they cannot stop using the substance. The disorder has an impact on physical and mental health, and the probability of developing other diseases, including depression and anxiety (Memedovich et al., 2018). It was established that the most suitable treatment strategy involves the use of behavioral therapies in combination with pharmacotherapy (McElrath, 2018).

### Causes and Risk Factors

The factors that lead to SUD and the factors that put one at risk for developing SUD are both genetic, environmental, and psychological. Genetically, people can be put at risk of developing an addiction problem with research showing that drug use has a genetic link (Goldman et al., 2020). Other specialized factors include peer pressure, family history of substance use, and economic pressures as well (Grant et al., 2017). Other influences are trauma, mental disorders, coping mechanisms, and experience, and lastly, stress also triggers SUD (Kamens et al., 2023). That is why awareness of these risk factors is quite crucial for planning primary and secondary prevention measures.

### The Impact of SUD on Individuals and Society

SUD not only affects a person but also one's family and the whole society, and that establishes that SUD has a broad effect. On an individual level, SUD results in declined health and well-being, family and marital discord, social isolation unemployment, or poor work productivity (Memedovich et al., 2018). The economic impact of SUD is high since it entails expenditure which includes, health, criminal justice, and productivity loss (NIDA, 2021) as shown in Table 1. On an individual level, substance use results in early mortality, poor health, and loss of productivity, whereas on a societal level, it leads to increased crime, family dysfunction, societal instability, and a burden to health systems. Mitigation of these consequences hence needs multimodal, extensive goal-driven strategies that include prevention, treatment, and minimizing effects of this substance (Mercer et al., 2017).

**Table 1: Key Aspects of Substance Use Disorder (SUD) and Its Impact on Individuals and Society**

Topic	Definition	Criteria	Causes	Risk Factors	Impact on Individuals	Impact on Society	Treatment	References
Substance Use Disorder (SUD)	Persistent and compulsive use of psychoactive substances	Inability to control use, cravings, and continued use despite harm	Genetic factors, environmental influences, psychological factors	Peer pressure, family history, trauma, stress	Decline in health, social isolation, unemployment	Increased crime, family dysfunction, societal instability	Behavioral therapies and pharmacotherapy	(Cooper, 2018)
Causes and Risk Factors	Genetic, environmental, and psychological factors	-	Genetic predisposition to addiction	Peer pressure, family history, economic pressures	Mental health issues, coping mechanisms, trauma	Stress, exposure to substance use in social circles	-	(Grant et al., 2017)
Impact on Health	Affects physical and mental health, and increases the risk of other diseases	-	-	Stress and trauma affecting mental health	Physical illness, mental disorders, and co-occurring conditions	Increased healthcare costs, the burden on health systems	Address through combined medical and behavioral approaches	(Memedovich et al., 2018)
Impact on Family and Social Life	Family discord, social isolation, poor work productivity	-	Family history of substance use, peer influences	Family and marital discord, difficulty maintaining relationships	Social stigma, reduced quality of life, family dysfunction	Family conflict, increased burden on social services	-	(Memedovich et al., 2018)
Economic Impact	High economic burden due to healthcare, criminal justice, and productivity loss	-	-	Economic pressures from substance use	High healthcare costs, loss of workforce productivity	Loss of workforce, economic instability	Policies addressing economic burden and healthcare costs	(Kamens et al., 2023)
Mortality and Early Death	Increased risk of premature death due to substance use	-	Drug overdose, comorbidities, high-risk behaviors	High-risk behavior, lack of treatment access	Early mortality, chronic health issues, impaired quality of life	Increased mortality rate and healthcare costs	Preventive and early intervention strategies	(Memedovich et al., 2018)

Prevention and Intervention	Need for prevention and treatment strategies	Primary and secondary prevention strategies	Family and peer support, public health interventions	Address stress, trauma, and mental health	Focus on primary and secondary prevention efforts	Large-scale social programs to reduce addiction rates	Multimodal strategies including public health, treatment programs, and rehabilitation	(McElrath, 2018)
-----------------------------	--	---	--	---	---	---	---	------------------

### 3. PREVENTION STRATEGIES

#### Primary Prevention: Focus on At-Risk Populations

Primary prevention has as its goal the complete avoidance of the use of substances and is especially targeted at specific groups of the population students, persons with a family history of addiction, and people with low income. School-based educational programs are one of the most effective approaches when it comes to preventing substance use among young persons (Conway et al., 2016). Some of these programs include Life Skills Training which has been found to decrease the probability of substance initiation (Hennessy & Tanner, 2015). Other approaches to primary prevention include community mobilization efforts that foster health-supporting norms and help eliminate substance use (Passmore & Whybrow, 2019).

#### Secondary Prevention: Early Intervention and Screening

Secondary prevention aims at patients who have initiated substance use but have not reached the level of substance use disorder (Hartman et al., 2023). Screening and Brief Intervention (SBI) for instance are services that enable early detection of risky practices. Stark and longitudinal results also exist that show properly conducted SBI in the healthcare context helps decrease alcohol use and its negative effects (Ghany et al., 2020). Tools like AUDIT can be used for identifying the people in detail and risk appraisal to provide treatment before the condition worsens into dangerous substance dependency forms (Wardell et al., 2020). These interventions assist in an attempt to curb the progression of substance use disorders.

#### Tertiary Prevention: Harm Reduction Approaches

Tertiary prevention is performed with clients with previous substance use disorders and its purpose is to minimize the negative consequences of substance use. For instance, needle exchange services give out new needles to avoid infection of HIV and other diseases in the sub-group of persons who use drugs intravenously (Needle et al., 2017). Take for instance, safe consumption spaces – these are set places equipped with medical oversight where substance users access and take substances in controlled situations to minimize the chance of overdose (Ng et al., 2017) as shown in Figure 2. These strategies have been postulated to decrease harm, enhance health, and decrease the social cost of substance use (Platt et al., 2018).




Figure 2: Prevention Strategies

### 4. INTERVENTION STRATEGIES

#### Behavioral and Psychological Interventions: Cognitive Behavioral Therapy (CBT)

One of the best-known psychological treatments for SUD is Cognitive Behavioral Therapy (CBT). CBT is centered on the belief that people develop irrational beliefs that lead to the development of addiction. People attend organized meetings



where they get to know how to develop coping techniques, problem-solving skills, and thought restructuring to manage cravings and avoid relapse (Easton et al., 2018). Research has shown that CBT decreases substance use and enhances psychological well-being and thus probably constitutes one of the top treatments for alcoholism and illicit drug dependence (Ray et al., 2020). Combining CBT with other therapeutic models increases its effectiveness in maintaining progress in the course of the long-term treatment process (Miller & Moyers, 2017).

### **Behavioral and Psychological Interventions: Motivational Interviewing (MI)**

Motivational Interviewing (MI) is an affirmative, directive counseling approach focused on increasing an individual's intrinsic motivation to change the identified problematic behaviors. The way that MI operates is by reducing internal conflict and promoting self-belief by use of attentive listening, asking permissive questions, and offering affirmations as suggested by Miller & Moyers (2017). The findings of the research indicate that MI is useful in encouraging behavior change in substance use besides being used in conjunction with other therapies like CBT (Carra et al., 2020). MI is commonly applied in early intervention contexts and has been reported to have favorable functions for decreasing alcohol and drug misuse, encouraging entry into treatment, and enhancing retention rates in addiction treatment programs (Martino et al., 2014).

### **Pharmacological Interventions: Medications for Alcohol and Opioid Use Disorders**

Medications are an important part of treating SUD, especially Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). Antabuse or disulfiram, acamprosate, and naltrexone are some of the drugs that are prescribed for the treatment of alcohol use disorder (Lesch et al., 2020). For opiate addiction, the medication treatments include methadone, buprenorphine, and naltrexone, which have been perceived as effective in managing cravings and preventing relapse (McElrath, 2018). These drugs treat addiction by changing the neural circuits that control substance dependence and enhance the client's recovery process. Medical management interventions are most effective when complemented by pharmacological management and psychotherapy or other behavioral approaches (Magill et al., 2019).

### **Pharmacological Interventions: Medication-Assisted Treatment (MAT)**

Medication-assisted treatment or MAT integrates the use of medications alongside individual and/or group counseling and behavioral therapies to treat substance use disorders. MAT has had its effectiveness identified in the treatment of opioid and alcohol dependence, as it focuses on the biological and psychological aspects of the disease (Magill et al., 2013). Available literature shows that MAT has the following benefits it increases retention in treatment, decreases use of illicit substances, and optimizes functioning (Marie et al., 2017). In addition, MAT decreases the likelihood of overdose and related death by stabilizing patients and avoiding withdrawal signs (Memedovich et al., 2018). It is thought to be the optimum intervention for opioid use disorder (Oesterle et al., 2019).

### **Integrated Approaches: Dual Diagnosis Treatment**

Dual diagnosis is commonplace, and therefore, dual treatment using techniques from different treatment models is crucial while treating such patients. Integrated treatment of mental disorders and substance use disorders is provided as these disorders present a high level of interaction (Mueser et al., 2013). Kim (2015) has pointed out that dual diagnosis treatments coordinate medical and psychological treatments that are appropriate for the client. The research indicates that the use of integrated treatment programs is ideal for dual diagnosis since it results in better treatment retention, reduced substance use, and improved mental health functioning (Carroll & Kiluk, 2017).

### **Integrated Approaches: Multidisciplinary Teams**

Due to such complexities intervention services for substance use disorders rely on a multidisciplinary team, especially in scenarios with dual diagnosis or cofactors (Breijyeh et al., 2021). Members of these teams often comprise psychiatrists, clinical social workers, psychologists, nurses, and addiction counselors who deal with comprehensive patient care (Glover et al., 2014) as shown in Table 2. A literature review has also revealed that care is delivered more effectively by a multidisciplinary team since all aspects of a patient's health are considered (Kaufmann et al., 2015). It is also important since integrated care increases continuity of care and patient satisfaction due to a single, personalized treatment plan (Barlow et al., 2020).

**Table 2: Intervention Strategies for Substance Use Disorder (SUD)**

Intervention Strategy	Definition	Key Approach	Treatment Focus	Methods Used	Effectiveness	Benefits	Challenges	References
Cognitive Behavioral Therapy (CBT)	Psychological treatment focuses on changing irrational beliefs	Coping techniques, problem-solving, thought restructuring	Alcoholism and illicit drug dependence	Structured therapy, through restructuring	Decreases substance use, enhances psychological well-being	Reduces cravings, prevents relapse	Requires long-term commitment	(Miller & Moyers, 2017)
Motivational Interviewing (MI)	Counseling approach to increase intrinsic motivation for change	Attentive listening, affirmations, and permissive questioning	Encourages behavior change, enhances self-belief	Directive counseling, supportive questioning	Increases motivation, promotes behavior change	Enhances treatment retention, reduces alcohol and drug misuse	May not work in the later stages of addiction	(Miller & Rollnick, 2024)
Medications for Alcohol and Opioid Disorders (AUD/OD)	Medication-based treatment for alcohol and opioid use disorders	Naltrexone, disulfiram, methadone, buprenorphine	Treats alcohol and opioid addiction	Medications for craving reduction, relapse prevention	Helps in managing cravings, reduces relapse	Supports long-term recovery, improves client functioning	Risk of side effects, dependency on medications	(McElrath, 2018)
Medication-Assisted Treatment (MAT)	Combination of medications and counseling for SUD treatment	Medications with behavioral therapy	Opioid and alcohol disorders	Medication with individual/group counseling	Improves retention, reduces illicit drug use	Decreases overdose deaths, stabilizes patients	High cost of treatment, patient adherence	(Oosterleet et al., 2019)
Dual Diagnosis Treatment	Integrated treatment for individuals with both mental and substance use disorders	Combination of psychological and medical treatments	Dual diagnosis (substance use + mental health disorders)	Coordinated medical and psychological treatment	Improves treatment retention, reduces substance use	Enhances mental health functioning, supports recovery	Complex treatment requires skilled professionals	(Carroll & Kiluk, 2017)
Multidisciplinary Teams	Team-based care involving multiple healthcare professionals	Collaboration among various health experts	Comprehensive treatment for complex cases	Psychiatrists, social workers, psychologists, addiction counselors	Increasing the effectiveness of treatment enhances patient care	Improves continuity of care, personalized treatment plans	Coordination and communication challenges among team members	(Kaufmann et al., 2015)

## 5. CHALLENGES IN PREVENTION AND INTERVENTION

### Stigma and Social Barriers

Pride or shame related to substance use continues to be an important factor that hinders prevention and treatment. Substance use disorder patients suffer from social isolation and hence are reluctant to seek help (Tostes et al., 2020). The current view of addiction as the failure of character instead of disease serves the same purpose and hinders those who suffer from addiction from getting the requisite treatment. Self-inclusion also leads to rejection and seclusion can worsen the mental health of a person and slow their healing (Rueda et al., 2016). The above social factors should thus be dealt with to enhance participation in the prevention and treatment programs and services (Petry et al., 2017).


### Lack of Resource Availability and Treatment

Treatment of substance use disorders involves the management of withdrawal symptoms and the use of drugs to do that, more so the lack of Access to resources and treatment options to address substance use disorders is still a major challenge (Florence et al., 2016). In many areas presently, there is a shortage of health professionals especially in rural and remote areas hence every person cannot obtain the care he/she deserves (Cher et al., 2019). Also, the long waiting lists for treatment services and low insurance reimbursement rates for substance use disorder treatment limit access to appropriate treatment (Abuse, 2020). To fill these gaps, policymakers must increase the number of treatment settings, bring addiction into the primary care settings, and ensure increased insurance coverage (Davis et al., 2016).

### Policy and Funding Gaps

Funding remains a major problem and so do insufficient policies implemented for the prevention and management of substance use disorders. The problem is that current government spending for addiction treatment and prevention services

is insufficient to support the development and expansion of those services (Friedmann et al., 2015). Today, a large number of regions do not have policies that address the integration of addiction treatment into primary care settings, which leads to the development of a rather fragmented system of care (Kertesz et al., 2014). Additionally, the lack of policy coherence for substance use treatment across states and countries contributes to the formulation of integrated strategies for addressing the global problem of addiction as shown in Figure 3. Each of these policy and funding issues must be resolved to increase the range and improve the standard of addiction treatment.



**Figure 3: Challenges in substance use disorder treatment**

## 6. EMERGING TRENDS IN PREVENTION AND INTERVENTION

### Virtual treatment and telemedicine services

The use of telehealth and virtual treatment platforms has become an important modality to prevent and treat SUD (Csete et al., 2016). The opportunity to get therapy and support through the help of online platforms allows using the services for those who live in rural or other poorly drawer areas (Huskamp et al., 2018). Telehealth meets people in their comfort and allows individuals to engage in counseling, group therapy, and monitoring without feeling or appearing mentally ill (Bashshur et al., 2016). Other research has indicated that telehealth is an effective approach to SUD treatment as it is as effective as face-to-face sessions (Lin et al., 2019). Telehealth is set to grow further in the future as technology moves on in its capacity to offer addiction treatment (Acharibasam & Wynn, 2018).

### Mutual Support and Recovery Mentorship

Peer support and recovery coaching have become popular as adjuncts to traditional treatment for persons with SUD (Volkow et al., 2019). Peer recovery support staff including Individuals in Recovery, give supportive, educational, and resourceful assistance, and counsel the clients to overcome the demands of recovery (Baird, 2016). A study has indicated that peer support increases the likelihood of clients' adherence to their treatment plans and lowers the incidences of relapse as well as boosts recovery over the long term (Abdollahpour et al., 2015). Any kind of clinical treatment that uses peer support contributes to the development of the community and empowered status – the factors that were found to be essential for recovery (Acharibasam & Wynn, 2018). Self-help support is becoming a significant part of the complex treatment of addiction (Tracy & Wallace, 2016).

### Pharmacogenomics Today: Personalized Medicine for Tomorrow

Substance use disorder treatment is being transformed by pharmacogenomic therapies that depend on the person's ancestry (Gordon et al., 2020). Genetic testing can also predict the reaction of a patient to some drugs making the healthcare

providers give the best treatment that will increase the efficiency of the drug as well as minimize the side effects (Jones et al., 2015). In the case of SUD, pharmacogenomic studies have also mainly focused on genes that determine the efficacy of drugs such as methadone and naltrexone in the treatment of opioid dependence (Bauer et al., 2015) as shown in Table 3. This relatively new area has the potential to enhance pharmacological treatments, decrease relapse, and enhance treatment outcomes due to better compatibility of patients with a certain treatment (Deak & Johnson, 2021).

**Table 3: Emerging Trends in Prevention and Intervention for SUD**

Trend	Description	Advantages	Challenges	Implementation Examples	Target Population	Effectiveness	Future Potential	Reference
Virtual Treatment and Telemedicine	Use of online platforms to deliver therapy, group sessions, and monitoring remotely.	Accessible to rural populations, flexible scheduling, reduces stigma	Limited access to technology, and privacy concerns.	Telehealth platforms like BetterHelp, and Teladoc.	Rural residents, underserved communities.	As effective as in-person therapy	Increasing scope with advancements in technology.	(Lin et al., 2019)
Mutual Support and Recovery Mentorship	Peer-based support programs involving individuals in recovery assisting others.	Enhances adherence, reduces relapse, and boosts community building	Requires well-trained mentors, not a standalone treatment	Peer support networks and coaching initiatives.	Individuals with limited access to professional care.	Proven long-term benefits	Growing role in integrated care models.	(Abdollahpour et al., 2015)
Pharmacogenomics	Personalized medicine approach based on genetic testing to enhance treatment outcomes.	Optimizes drug efficacy and minimizes side effects	High costs, and limited access to genetic testing	Genetic testing is integrated into treatment plans.	Patients are resistant to traditional therapies.	Promising results in reducing relapse	Significant advancements are expected in pharmacology.	(Deak, & Johnson, 2021)
Smartphone-Based Interventions	Apps designed for addiction management, including reminders, relapse prevention, and virtual support.	Convenient, constant access, and anonymity	Requires tech literacy, and potential for misuse.	Apps like Sober Grid, and Pocket Rehab.	Tech-savvy individuals, younger demographics.	High engagement rates	Expansion of app features for comprehensive care.	(Magill et al., 2019)
Virtual Reality Therapy	Immersive VR environments to simulate triggers and teach coping mechanisms.	Interactive, controlled environment for exposure therapy	Expensive, and requires specialized equipment.	VR platforms for addiction recovery.	Patients with high relapse rates.	Effective for behavioral therapy	Expected to revolutionize behavioral interventions.	(Deak & Johnson, 2021)
Artificial Intelligence (AI)	AI-based platforms analyze behavior and provide personalized treatment recommendations.	Data-driven insights improve precision medicine	Privacy issues, and algorithm bias	AI in telemedicine and virtual addiction treatment.	All patient demographics.	Early stages but promising (Chung et al., 2020).	Key role in future diagnostic and intervention models.	(Abdollahpour et al., 2015)
Wearable Technology	Devices to monitor vitals and detect relapse signs through physiological changes.	Continuous monitoring, and early intervention	Privacy and accuracy concerns, high initial cost.	Wearables like Fitbit and smartwatches for addiction care.	Patients undergoing long-term treatment.	Improves patient compliance and monitoring	Integration with other telehealth platforms.	(Bauer et al., 2015)



## 7. CONCLUSION

The prevention and intervention strategies for SUD have changed over the recent past with new trends presenting new opportunities for effective treatment. Telehealth and virtual treatment platforms have increased opportunities, allowing people to receive nondescript, remote treatment, especially for those in the periphery. Peer support and recovery coaching are quite effective in increasing treatment participation rates and decreasing relapse rates, the key role of peer support in recovery pathways. Moreover, progress in pharmacogenomics means that pharmacological therapy can be adjusted to the genetic characteristics of treatment recipients, and thus enhance the effectiveness of interventions for SUD patients. However, barriers like stigma, social barriers, and resource constraints are still experienced meaning that more effort is needed to close these gaps. For future studies, long-term outcomes of virtual treatment platforms and the use of peer support models among understudied populations should be considered. There is also a need for more large-scale pharmacogenomics to expand the full potential in the treatment of SUD. Telehealth services should be included in traditional health and medical care, equal access to treatment should be provided, and innovative recovery programs should be financed. Furthermore, the co-authoring of policy, practitioners, and scholars for the provision of an effective, available, and tailored SUD prevention and intervention approach is required for the enhancement of the recovery and reduction of the societal impacts of addiction.

## REFERENCES

1. Abdollahpour, S., Ramezani, S., & Khosravi, A. (2015). Perceived social support among family in pregnant women.
2. Abuse, S. (2020). Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health.
3. Acharibasam, J. W., & Wynn, R. (2018). Telemental Health in Low-and Middle-Income Countries: A Systematic Review. *International Journal of Telemedicine and Applications*, 2018(1), 9602821.
4. Baird, C. (2016). Recovery Management and Recovery-Oriented Systems of Care. *Journal of Addictions Nursing*, 27(2), 151-153.
5. Breijyeh, Z., Jubeh, B., Bufo, S. A., Karaman, R., & Scrano, L. (2021). Cannabis: a toxin-producing plant with potential therapeutic uses. *Toxins*, 13(2), 117.
6. Barlow, D. H., Allen, L. B., & Choate, M. L. (2020). Toward a unified treatment for emotional disorders. In *The Neurotic Paradox, Volume 1* (pp. 141-166). Routledge.
7. Bashshur, R. L., Howell, J. D., Krupinski, E. A., Harms, K. M., Bashshur, N., & Doarn, C. R. (2016). The empirical foundations of telemedicine interventions in primary care. *Telemedicine and e-Health*, 22(5), 342-375.
8. Bauer, I. E., Soares, J. C., & Nielsen, D. A. (2015). The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: a systematic review. *The American Journal on Addictions*, 24(1), 15-23.
9. Bonk, R., Miller, R. J., Lanter, J., Niblo, C., Kemp, J., & Shelton, J. (2020). Accidental overdose deaths in Oklahoma, 2002–2017: Opioid and methamphetamine trends. *Journal of Analytical Toxicology*, 44(7), 672-678.
10. Carra, M. C., Detzen, L., Kitzmann, J., Woelber, J. P., Ramseier, C. A., & Bouchard, P. (2020). Promoting behavioral changes to improve oral hygiene in patients with periodontal diseases: A systematic review. *Journal of Clinical Periodontology*, 47, 72-89.
11. Cher, B. A., Morden, N. E., & Meara, E. (2019). Medicaid expansion and prescription trends: opioids, addiction therapies, and other drugs. *Medical care*, 57(3), 208-212.
12. Conway, K. P., Swendsen, J., Husky, M. M., He, J. P., & Merikangas, K. R. (2016). Association of lifetime mental disorders and subsequent alcohol and illicit drug use: results from the National Comorbidity Survey–Adolescent Supplement. *Journal of the American Academy of Child & Adolescent Psychiatry*, 55(4), 280-288.
13. Cooper, R. (2018). *Diagnosing the diagnostic and statistical manual of mental disorders*. Routledge.
14. Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., ... & Beyrer, C. (2016). Public health and international drug policy. *The Lancet*, 387(10026), 1427-1480.
15. Davis, D. R., Kurti, A. N., Skelly, J. M., Redner, R., White, T. J., & Higgins, S. T. (2016). A review of the literature on contingency management in the treatment of substance use disorders, 2009–2014. *Preventive medicine*, 92, 36-46.
16. Deak, J. D., & Johnson, E. C. (2021). Genetics of substance use disorders: a review. *Psychological medicine*, 51(13), 2189-2200.
17. Easton, C. J., Crane, C. A., & Mandel, D. (2018). A randomized controlled trial assessing the efficacy of cognitive behavioral therapy for substance-dependent domestic violence offenders: an integrated substance abuse-domestic violence treatment approach (SADV). *Journal of marital and family therapy*, 44(3), 483-498.
18. Fernandes, R. M., Cary, M., Duarte, G., Jesus, G., Alarcão, J., Torre, C., ... & Carneiro, A. V. (2017). Effectiveness of needle and syringe Programmes in people who inject drugs—An overview of systematic reviews. *BMC Public Health*, 17, 1-15.
19. Florence, C. S., Zhou, C., Luo, F., & Xu, L. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. *Medical care*, 54(10), 901-906.

20. Friedmann, P. D., Wilson, D., Knudsen, H. K., Ducharme, L. J., Welsh, W. N., Frisman, L., ... & Vocci, F. J. (2015). Effect of an Organizational linkage Intervention on Staff perceptions of medication-assisted treatment and Referral Intentions in community corrections. *Journal of substance abuse treatment*, 50, 50-58.
21. Ghany, M. G., Morgan, T. R., & AASLD-IDSA hepatitis C guidance panel. (2020). Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. *Hepatology*, 71(2), 686-721.
22. Goldman, D., Ducci, F., & Gitik, M. (2020). Familial genetics of psychopathic disorders. *The Wiley international handbook on psychopathic disorders and the law*, 159-187.
23. Gordon, A. J., Drexler, K., Hawkins, E. J., Burden, J., Codell, N. K., Mhatre-Owens, A., ... & Hagedorn, H. (2020). Article commentary: stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within veterans health administration facilities. *Substance Abuse*, 41(3), 275-282.
24. Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., ... & Hasin, D. S. (2017). Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA psychiatry*, 74(9), 911-923.
25. Hartman, C. A., Larsson, H., Vos, M., Bellato, A., Libutzki, B., Solberg, B. S., ... & Reif, A. (2023). Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit/hyperactivity disorder: a substantive and methodological overview. *Neuroscience & Biobehavioral Reviews*, 151, 105209.
26. Helle, A. C., Boness, C. L., & Sher, K. J. (2022). College students' receptiveness to intervention approaches for alcohol and cannabis use. *Psychology of Addictive Behaviors*, 36(2), 157.
27. Hennessy, E. A., & Tanner-Smith, E. E. (2015). Effectiveness of brief school-based interventions for adolescents: A meta-analysis of alcohol use prevention programs. *Prevention Science*, 16, 463-474.
28. Jones, J. D., Comer, S. D., & Kranzler, H. R. (2015). The pharmacogenetics of alcohol use disorder. *Alcoholism: Clinical and Experimental Research*, 39(3), 391-402.
29. Kamens, H. M., Cramer, S., Hanley, R. N., Chase, S., Wickenheisser, A., Horton, W. J., & Zhang, N. (2023). Neuroimaging of opioid exposure: a review of preclinical animal models to inform addiction research. *Psychopharmacology*, 240(12), 2459-2482.
30. Kaufmann, C. P., Stämpfli, D., Hersberger, K. E., & Lampert, M. L. (2015). Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. *BMJ open*, 5(3), e006376.
31. Kim, K. (2015). The processing and treatment of mentally ill persons in the criminal justice system.
32. Lesch, O. M., Walter, H., Wetschka Ch, H. M., & Hesselbrock, V. (2020). *Alcohol and tobacco*. Springer International Publishing.
33. Lin, L. A., Casteel, D., Shigekawa, E., Weyrich, M. S., Roby, D. H., & McMenamin, S. B. (2019). Telemedicine-delivered treatment interventions for substance use disorders: A systematic review. *Journal of substance abuse treatment*, 101, 38-49.
34. Magill, M., Ray, L., Kiluk, B., Hoadley, A., Bernstein, M., Tonigan, J. S., & Carroll, K. (2019). A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. *Journal of consulting and clinical psychology*, 87(12), 1093.
35. Marie-Claire, C., Jourdain, C., Lépine, J. P., Bellivier, F., Bloch, V., & Vorspan, F. (2017). PhPharmacogenomics of opiates and methadone maintenance therapy: Current data and perspectives. *Pharmacogenomics*, 18(14), 1359-1372.
36. McElrath, K. (2018). Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. *Substance Use & Misuse*, 53(2), 334-343.
37. Memedovich, K. A., Dowsett, L. E., Spackman, E., Noseworthy, T., & Clement, F. (2018). The adverse health effects and harms related to marijuana use: an overview review. *Canadian Medical Association Open Access Journal*, 6(3), E339-E346.
38. Memedovich, K. A., Dowsett, L. E., Spackman, E., Noseworthy, T., & Clement, F. (2018). The adverse health effects and harms related to marijuana use: an overview review. *Canadian Medical Association Open Access Journal*, 6(3), E339-E346.
39. Mercer Lindsay, N., Chen, C., Gilam, G., Mackey, S., & Scherrer, G. (2021). Brain circuits for pain and its treatment. *Science translational medicine*, 13(619), eabj7360.
40. Miller, W. R., & Moyers, T. B. (2017). Motivational interviewing and the clinical science of Carl Rogers. *Journal of consulting and clinical psychology*, 85(8), 757.
41. Miller, W. R., & Rollnick, S. (2024). Why motivational interviewing is a person-centered approach. *Sucht*.

42. Misra, S., Jackson, V. W., Chong, J., Choe, K., Tay, C., Wong, J., & Yang, L. H. (2021). Systematic review of cultural aspects of stigma and mental illness among racial and ethnic minority groups in the United States: Implications for interventions. *American journal of community psychology*, 68(3-4), 486-512.
43. Naslund, J. A., Aschbrenner, K. A., Marsch, L. A., & Bartels, S. J. (2016). The future of mental health care: peer-to-peer support and social media. *Epidemiology and psychiatric sciences*, 25(2), 113-122.
44. Needle, R. H., Burrows, D., Friedman, S. R., Dorabjee, J., Touzé, G., Badrieva, L., ... & Latkin, C. (2017). Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. In *Drug Abuse: Prevention and Treatment* (pp. 189-201). Routledge.
45. Ng, J., Sutherland, C., & Kolber, M. R. (2017). Does evidence support supervised injection sites? *Canadian Family Physician*, 63(11), 866-866.
46. Oesterle, T. S., Thusius, N. J., Rummans, T. A., & Gold, M. S. (2019, October). Medication-assisted treatment for opioid-use disorder. In *Mayo Clinic Proceedings* (Vol. 94, No. 10, pp. 2072-2086). Elsevier.
47. Passmore, J., & Whybrow, A. (2019). Motivational interviewing. *The handbook of coaching psychology*. London: Brunner-Routledge.
48. Petry, N. M., Alessi, S. M., Olmstead, T. A., Rash, C. J., & Zajac, K. (2017). Contingency management treatment for substance use disorders: How far has it come, and where does it need to go? *Psychology of Addictive Behaviors*, 31(8), 897.
49. Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., ... & Hickman, M. (2018). Needle and syringe programs and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. *Addiction*, 113(3), 545-563.
50. Ray, L. A., Meredith, L. R., Kiluk, B. D., Walthers, J., Carroll, K. M., & Magill, M. (2020). Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. *JAMA Network open*, 3(6), e208279-e208279.
51. Rueda, S., Mitra, S., Chen, S., Gogolishvili, D., Globerman, J., Chambers, L., ... & Rourke, S. B. (2016). Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. *BMJ open*, 6(7), e011453.
52. Tostes, J. G. D. A., Dias, R. T., Reis, A. A. D. S., Silveira, P. S. D., & Ronzani, T. M. (2020). Interventions to reduce stigma related to people who use drugs: systematic review. *Paidéia (Ribeirão Preto)*, 30, e3022.
53. Tracy, K., & Wallace, S. P. (2016). Benefits of peer support groups in the treatment of addiction. *Substance abuse and rehabilitation*, 143-154.
54. Volkow, N. D., Michaelides, M., & Baler, R. (2019). The neuroscience of drug reward and addiction. *Physiological reviews*, 99(4), 2115-2140.
55. Wardell, J. D., Cunningham, J. A., Quilty, L. C., Carter, S., & Hendershot, C. S. (2020). Can the AUDIT consumption items distinguish lower severity from high severity patients seeking treatment for alcohol use disorder? *Journal of Substance Abuse Treatment*, 114, 108001.